ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer
Crossref DOI link:
Update policy: https://doi.org/10.1007/SPRINGER_CROSSMARK_POLICY
Text and Data Mining valid from 2021-10-29
Version of Record valid from 2021-10-29
24 August 2021
14 October 2021
29 October 2021
All authors approved for the publication.
The authors declared no conflict of interests.